234 related articles for article (PubMed ID: 31664040)
1. TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
Xu Y; Man N; Karl D; Martinez C; Liu F; Sun J; Martinez CJ; Martin GM; Beckedorff F; Lai F; Yue J; Roisman A; Greenblatt S; Duffort S; Wang L; Sun X; Figueroa M; Shiekhattar R; Nimer S
Nat Commun; 2019 Oct; 10(1):4925. PubMed ID: 31664040
[TBL] [Abstract][Full Text] [Related]
2. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.
Yang E; Guan W; Gong D; Gao X; Han C; Zhang J; Wang H; Wang M; Li Y; Yu L
Clin Sci (Lond); 2020 Dec; 134(23):3079-3091. PubMed ID: 33201243
[TBL] [Abstract][Full Text] [Related]
4. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
5. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
6. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.
Liu N; Song J; Xie Y; Wang XL; Rong B; Man N; Zhang MM; Zhang Q; Gao FF; Du MR; Zhang Y; Shen J; Xu CH; Hu CL; Wu JC; Liu P; Zhang YL; Xie YY; Liu P; Huang JY; Huang QH; Lan F; Shen S; Nimer SD; Chen Z; Chen SJ; Roeder RG; Wang L; Sun XJ
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):890-899. PubMed ID: 30593567
[TBL] [Abstract][Full Text] [Related]
7. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Schnoeder TM; Schwarzer A; Jayavelu AK; Hsu CJ; Kirkpatrick J; Döhner K; Perner F; Eifert T; Huber N; Arreba-Tutusaus P; Dolnik A; Assi SA; Nafria M; Jiang L; Dai YT; Chen Z; Chen SJ; Kellaway SG; Ptasinska A; Ng ES; Stanley EG; Elefanty AG; Buschbeck M; Bierhoff H; Brodt S; Matziolis G; Fischer KD; Hochhaus A; Chen CW; Heidenreich O; Mann M; Lane SW; Bullinger L; Ori A; von Eyss B; Bonifer C; Heidel FH
Blood; 2022 Feb; 139(7):1080-1097. PubMed ID: 34695195
[TBL] [Abstract][Full Text] [Related]
8. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
[TBL] [Abstract][Full Text] [Related]
10. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.
Saeed S; Logie C; Francoijs KJ; Frigè G; Romanenghi M; Nielsen FG; Raats L; Shahhoseini M; Huynen M; Altucci L; Minucci S; Martens JH; Stunnenberg HG
Blood; 2012 Oct; 120(15):3058-68. PubMed ID: 22923494
[TBL] [Abstract][Full Text] [Related]
11. The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.
Chou FS; Griesinger A; Wunderlich M; Lin S; Link KA; Shrestha M; Goyama S; Mizukawa B; Shen S; Marcucci G; Mulloy JC
Blood; 2012 Jul; 120(4):709-19. PubMed ID: 22337712
[TBL] [Abstract][Full Text] [Related]
12. Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel VN; Giaimo BD; Schwarz P; Soller K; Vas V; Bartkuhn M; Blätte TJ; Döhner K; Bullinger L; Borggrefe T; Geiger H; Oswald F
Leukemia; 2017 Nov; 31(11):2491-2502. PubMed ID: 28360416
[TBL] [Abstract][Full Text] [Related]
13. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
14. A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
Lin S; Ptasinska A; Chen X; Shrestha M; Assi SA; Chin PS; Imperato MR; Aronow BJ; Zhang J; Weirauch MT; Bonifer C; Mulloy JC
Blood; 2017 Sep; 130(10):1213-1222. PubMed ID: 28710059
[TBL] [Abstract][Full Text] [Related]
15. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
[TBL] [Abstract][Full Text] [Related]
16. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.
Wang L; Gural A; Sun XJ; Zhao X; Perna F; Huang G; Hatlen MA; Vu L; Liu F; Xu H; Asai T; Xu H; Deblasio T; Menendez S; Voza F; Jiang Y; Cole PA; Zhang J; Melnick A; Roeder RG; Nimer SD
Science; 2011 Aug; 333(6043):765-9. PubMed ID: 21764752
[TBL] [Abstract][Full Text] [Related]
17. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.
Zhang Y; Wang J; Wheat J; Chen X; Jin S; Sadrzadeh H; Fathi AT; Peterson RT; Kung AL; Sweetser DA; Yeh JR
Blood; 2013 Jun; 121(24):4906-16. PubMed ID: 23645839
[TBL] [Abstract][Full Text] [Related]
18. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
[TBL] [Abstract][Full Text] [Related]
20. YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML.
Chen Z; Shao YL; Wang LL; Lin J; Zhang JB; Ding Y; Gao BB; Liu DH; Gao XN
Oncogene; 2021 Jun; 40(22):3786-3798. PubMed ID: 33958724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
